Concord Biotech Limited
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.
What Concord files
- Others42
- Investor Meet42
- Important20
- Board Meeting13
- PPTs7
- Dividend/Bonus4
Concord Biotech's Unit-II facility successfully completed inspections by Kenyan & Ugandan health authorities. This boosts its global growth journey, strengthens quality standards, and expands its international market footprint.
Concord Biotech successfully completed an ANVISA inspection at its Limbasi API facility. This strengthens its global manufacturing footprint, advancing international expansion and enhancing access to major pharmaceutical markets like Brazil, broadening the reach of its high-quality APIs.
Concord Biotech secured USFDA approval for Mycophenolate Mofetil oral suspension, an immunosuppressant. This product targets a US market estimated at US$ 30 million (approx ₹249 Cr), boosting the company's offerings and growth strategy.
Concord Biotech's board approved Q3 financial results. Consolidated net profit reached ₹63.64 Cr, impacted by a ₹3.27 Cr one-time employee benefit charge. Paritosh Trivedi was also appointed as the new Company Secretary and Compliance Officer.
Concord Biotech successfully completed a NAFDAC inspection at its Valthera Oral Solid Dosage Unit-2 facility. This reinforces the company's commitment to high quality, safety, and global regulatory compliance, supporting continued market access and operational stability.